Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Adult Dermatomyositis
NCT04999020Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of ravulizumab in dermatomyositis (DM), sponsored by Alexion Pharmaceuticals. Started Nov 2021; status: terminated.
02
Drugs
ravulizumab
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT04999020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999020.